Ltd.

YS Biopharma Announces Results of Extraordinary General Meeting and Responds to False Statements about the Meeting

by

GAITHERSBURG, Md., Feb. 16, 2024 /PRNewswire/ — YS Biopharma Co., Ltd. (Nasdaq: YS) (“YS Biopharma” or the “Company”), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced the results of its extraordinary general meeting (the “EGM”) held on February … Read more

Ono Enters into a Drug Discovery Collaboration and Option Agreement with Shattuck Labs to Generate Bifunctional Fusion Proteins

by

OSAKA, Japan, Feb. 14, 2024 /PRNewswire/ — Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO: Gyo Sagara; “Ono”) today announced that it has entered into a drug discovery collaboration and option agreement with Shattuck Labs, Inc. (Austin, Texas, USA; CEO: Taylor Schreiber; “Shattuck”) to generate bifunctional fusion proteins for pathways involved in autoimmune and inflammatory … Read more

Results of the Phase III INSPIRE Study on Qilu Pharmaceutical’s Iruplinalkib Published in the Journal of Thoracic Oncology

by

JINAN, China, Jan. 30, 2024 /PRNewswire/ — The interim analysis results from the phase III INSPIRE study of iruplinalkib developed by Qilu Pharmaceutical, which focuses on the first-line treatment of locally advanced or metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), have recently been featured in the Journal of Thoracic Oncology (Impact Factor=20.4), the … Read more

Brain Navi Announces 100th Surgical Procedure Completed Using NaoTrac

by

HSINCHU, Jan. 15, 2024 /PRNewswire/ — Brain Navi announced the completion of the 100th case utilizing its neurosurgical navigation robot NaoTrac. The 100th case has been performed by Neurosurgery Department Director Dr. Hao-Yu Chuang at Annan Hospital in Tainan, Taiwan. Brain Navi Completed 100th Surgical Procedure Using NaoTrac “It is my pleasure to be witnessing this … Read more

GenSci lance un centre mondial d’innovation à Shanghai

by

La création de ce centre démontre l’engagement de l’entreprise à fournir des solutions adaptées aux défis de la gynécologie et de la pédiatrie SHANGHAI, 25 décembre 2023 /PRNewswire/ — Changchun GeneScience Pharmaceutical (« GenSci »), une filiale de Changchun High-Tech Industries (Group), a organisé le 15 décembre une cérémonie de pose de la première pierre de son nouveau … Read more

GenSci Launches Global Innovation Hub in Shanghai

by

The Establishment of the Facility Demonstrates the Company’s Commitment to Delivering Differentiated Solutions to Gynecology and Pediatrics Challenges SHANGHAI, Dec. 22, 2023 /PRNewswire/ — Changchun GeneScience Pharmaceutical (“GenSci”), a subsidiary of Changchun High-Tech Industries (Group), held a groundbreaking ceremony for its new global headquarters and research & development (R&D) center at Shanghai Zhangjiang International Medical … Read more

Tsingke Congratulates iGEM 2023 SYSU-Software on Winning GOLD MEDAL for BioRocket Project

by

BEIJING and PARIS, Dec. 18, 2023 /PRNewswire/ — The 2023 International Genetically Engineered Machine Competition (iGEM), the global synthetic biology competition, concluded on November 5, 2023. Over 7,000 students from high schools and universities, organized into more than 400 teams worldwide, participated in this prestigious event. Among them, the Sun Yat-sen University Software Team (iGEM … Read more

Ping An Chairman Dr. Ma Mingzhe Receives Director of The Year Award from The Hong Kong Institute of Directors

by

HONG KONG and SHANGHAI, Nov. 26, 2023 /PRNewswire/ — Ping An Insurance (Group) Company of China, Ltd. (hereafter “Ping An”, the “Company” or the “Group”, HKEX: 2318 / 82318; SSE: 601318) is pleased to announce that Dr. Ma Mingzhe, Chairman of Ping An, has been honored by The Hong Kong Institute of Directors. His Director of … Read more

Foresee Pharmaceuticals to Present Phase 1/2 Fanconi Anemia Clinical Study Design for its ALDH2 activator FP-045 at the Fanconi Anemia Research Fund 2023 Scientific Symposium

by

TAIPEI, Taiwan, Sept. 30, 2023 /PRNewswire/ — Foresee Pharmaceuticals (TPEx: 6576), (“Foresee”) announced today that the company will present the clinical design of the FP-045 Phase 1/2 clinical Fanconi anemia clinical study (FuschiA study) currently being initiated, at the Fanconi Anemia Research Fund (FARF) 2023 Scientific Symposium taking place in Vancouver, BC, Canada from September … Read more

Foresee Pharmaceuticals Presents Data From its Aderamastat Program at The European Respiratory Society (ERS) International Congress 2023

by

Late-breaking oral presentation on the positive primary outcomes of aderamastat, a first-in-class, oral MMP-12 inhibitor in a Phase 2 Phase 2 proof-of-concept allergic asthma study, supporting potential novel anti-inflammatory mechanism for respiratory diseases. TAIPEI, Sept. 12, 2023 /PRNewswire/ — Foresee Pharmaceuticals (TPEx: 6576), (“Foresee”) announced today that the company presented the positive primary outcomes of … Read more